Collectively, we could conclude that SETD2 facilitates imatinib sensitivity in the CML cell lines through the increase in apoptotic events, having no influence on the cell cycle (Supporting Information Figure S2). Here, SETD2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.